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Centenary theme section: BLISTERING SKIN DISORDERS
SIGNIFICANCE
Dermatitis herpetiformis is an itchy, blistering rash, which 
occurs on the elbows, knees and buttocks. Dermatitis 
herpetiformis is considered a cutaneous manifestation 
of coeliac disease. Even though obvious gastrointestinal 
symptoms are rare in dermatitis herpetiformis, intestinal 
coeliac-type villous atrophy or inflammation is present at 
diagnosis. The diagnosis is confirmed by skin biopsy revea-
ling typical IgA deposits, and the majority of patients also 
have coeliac autoantibodies in the serum. The treatment of 
choice for dermatitis herpetiformis is a life-long gluten-free 
diet, which resolves the rash and enteropathy, increases 
quality of life, and offers a good long-term prognosis.
Dermatitis herpetiformis (DH) is an autoimmune skin 
disease that causes itchy, blistering rash, typically 
on the elbows, knees and buttocks. DH and coeliac 
disease share the same genetic background, gluten-
dependent enteropathy and antibody response against 
tissue transglutaminase. DH is currently considered a 
cutaneous manifestation of coeliac disease, and the 
prevailing hypothesis is that DH develops as a late ma-
nifestation of subclinical coeliac disease. The incidence 
of DH is decreasing contemporarily with the increasing 
incidence of coeliac disease. The IgA immune response 
in DH skin is directed against epidermal transglutami-
nase, while the autoantigen in the gut is tissue trans-
glutaminase. Granular IgA deposition in the papillary 
dermis is pathognomonic for DH, and is a finding used 
to confirm the diagnosis. The treatment of choice for 
DH is a life-long gluten-free diet, which resolves the 
rash and enteropathy, increases quality of life, and of-
fers a good long-term prognosis. 
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Dermatitis herpetiformis (DH) is an intensively itching skin disease, which causes papulovesicular eruption, 
predominantly on the elbows, knees and buttocks. DH 
is considered an autoimmune-based disease, since pat-
hognomonic granular immunoglobulin A (IgA) response 
in the dermis, directed against epidermal transglutaminase 
(TG3), and circulating autoantibodies against tissue trans-
glutaminase (TG2) and TG3 exist in DH (1, 2). Moreover, 
the predisposing genetic background, more specifically 
HLA DQ2 or DQ8 haplotypes, is a necessity for develop-
ment of the disease (3). DH is considered a specific variant 
of coeliac disease, manifesting primarily in the skin, but 
coeliac-type enteropathy also exists in DH, albeit more 
subtle than in coeliac disease (4). Currently approximately 
13% of patients with coeliac disease have DH (5, 6) and 
the highest reported prevalence of DH to date has been 
75 per 100,000 from Finland (5). The prevalence is lower 
in some areas of the globe and in specific populations, 
for example in Asia and in African-Americans (7, 8) and, 
overall, the geographical differences in the prevalence of 
DH and, likewise, coeliac disease, have been explained 
mainly by HLA genetics and wheat consumption habits 
(9). Also the incidence figures of DH have ranged from 
0.4 to 3.5/100 000/year, even in different studies perfor-
med in Europe or North America (5, 10). DH is typically 
diagnosed during adulthood, and the incidence of DH is 
highest in females and males aged 50–69 years (5, 6). 
Interestingly, the diagnostic age of DH has increased (5) 
and, although the reasons for this increase remain largely 
obscure, a possible explanation could be changes in die-
tary habits. Nonetheless, even though childhood diagnosis 
is rare in northern Europe (5, 6, 11) it seems to be more 
common in Italy and Hungary (12, 13).
The focus of this review is to describe the current, 
clinically relevant, concepts of DH diagnostics, treatment 
and prognosis. In addition, the close link between DH 
and coeliac disease is elaborated, and unique features 
of DH, the cutaneous manifestation of coeliac disease, 
are presented. 
SKIN MANIFESTATION OF COELIAC DISEASE
The clinical manifestations of DH were first described as 
early as 1884 by Louis Duhring (14) and, 4 years later, 
the classical abdominal and malabsorptive symptoms of 
coeliac disease were described by Samuel Gee (15). The 
link between DH and coeliac disease was found when 
Marks et al. (16) detected that coeliac-type enteropathy 
was also a common finding in DH, and importantly, 
when gluten-free diet (GFD), the treatment of choice in 
coeliac disease, was shown to heal small bowel mucosal 
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changes in DH, and to alleviate DH rash (17, 18). Subse-
quent family and genetic studies have coupled DH and 
coeliac disease even more convincingly together: DH 
and coeliac disease have been shown to occur often in 
the same families and even in monozygotic twins, and 
furthermore, predominantly HLA DQ2 and, more rarely, 
DQ8 haplotypes have been shown to be the predisposing 
haplotypes in both (19–21). Moreover, it has been shown 
that the phenotype of coeliac disease is not invariably 
constant, since it can convert from classical disease into 
DH, especially when dietary compliance is poor (22). 
A major breakthrough occurred in coeliac disease 
research in the 1990s when TG2 enzyme was identified 
as the autoantigen of the disease (23). Subsequently an 
enzyme-linked immunosorbent assay (ELISA)-based 
method for detecting TG2 antibodies was developed 
and found to be accurate in coeliac disease (24) and, 
furthermore, a similar TG2 antibody reaction was shown 
to occur in the serum of patients with DH (2). Moreover, 
TG2-targeted autoimmune response has been detected 
in the small bowel mucosa of untreated coeliac disease 
and DH patients (25, 26). 
DH, however, has some distinct features compared 
with coeliac disease in general. DH is more rarely diagno-
sed during childhood compared with coeliac disease (11, 
27). Furthermore, DH is slightly more common among 
males than females (5), which contradicts the female 
predominance known to exist in coeliac disease (6, 28). 
Moreover, the incidence of DH has decreased, but in 
coeliac disease a marked increase in the incidence figures 
has been detected (5, 6, 28). One prevailing hypothesis 
is that DH develops as a late manifestation of coeliac 
disease, affecting individuals with subclinical or neg-
lected coeliac disease. It has, moreover, been suggested 
that the TG3 immune response typical for DH develops 
as an epitope spreading phenomenon from an autoim-
mune response initially targeting TG2 (29). Coeliac-type 
dental enamel defects detected in adults diagnosed with 
DH indicate that these individuals were already sensi-
tive to gluten in early childhood (30). Moreover, the 
rarity of childhood DH and the changing phenotype of 
coeliac disease during poor dietary adherence support 
this hypothesis, and furthermore, the divergent trend of 
incidences of DH and coeliac disease also fits well with 
this hypothesis: better diagnostics of coeliac disease due 
to increased awareness, availability of accurate serum 
autoantibody tests, and screening of risk groups has 
resulted in a smaller pool of patients with undiagnosed 
coeliac disease and, consequently, fewer individuals with 
potential for development of DH. 
DIAGNOSING DERMATITIS HERPETIFORMIS
The suspicion of DH typically arises from the charac-
teristic skin symptoms, which are an intensely pruritic 
rash with small blisters and papules affecting most com-
monly the extensor surfaces of the elbows, knees and 
buttocks (Fig. 1a, b and Table I). Occasionally other 
sites, such as the scalp, face, upper back and neck, are 
also affected. There is individual variation in the seve-
rity of the rash and pruritus, but commonly due to the 
intense itch and scratching, the blisters are broken and 
only erosions, crusts and post-inflammatory hyperpig-
mentation are consequently present. Acral purpura is 
one, albeit quite rare, finding in DH and can be found 
either as a sole presentation or concomitantly with the 
typical DH rash (31–33). Despite the gluten-sensitive 
enteropathy, obvious gastrointestinal symptoms and 
signs of malabsorption are rare in DH, but some kind of 
abdominal symptoms have, however, been reported in up 
to one-third of patients (34, 35). Interestingly, although 
the clinical picture of coeliac disease has been shown to 
become milder and more heterogenic with increasingly 
common non-classical symptoms (36–38), it seems that 
the clinical picture and the severity of DH rash have 
remained quite unchanged during recent decades (39). 
Fig. 1. Clinical characteristics of dermatitits herpetiformis (DH). (a) 
A typical clinical picture of dermatitis herpetiformis (DH) with excoriated 
blisters and papules on the elbows and knees. (b) Intact and excoriated 
blisters, papules and crusts on the elbow. (c) Direct immunofluorescence 
(× 40) finding in DH; granular IgA deposits in the basal membrane zone 
and in the dermis.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
117Dermatitis herpetiformis
Theme issue: Blistering skin disorders
The differential diagnosis of DH includes other subepi-
dermal blistering diseases, especially linear IgA disease 
and bullous pemphigoid. In addition, other itchy skin 
diseases, such as atopic and nummular dermatitis, lichen 
planus, urticaria and scabies may sometimes be difficult 
to differentiate from scratched DH rash, although the 
typical predilection sites of these diseases differ from 
those of DH (40).
The gold-standard method to verify DH diagnosis 
is direct immunofluorescence (IF) examination, which 
shows the pathognomonic granular IgA deposits in the 
papillary dermis and/or at the dermoepidermal junction 
(Fig. 1c). IgA deposits are widespread, but not totally 
uniformly distributed in the skin of patients with DH, 
and therefore the ideal site for the diagnostic skin biopsy 
is uninvolved perilesional skin, where the deposits are 
found in greater amounts (41). The immune response 
in DH skin is directed against TG3, an enzyme closely 
related, but not identical, to TG2 (1). It has recently been 
demonstrated that TG3 disappears from the dermis of 
patients with DH on a GFD, in parallel with IgA, but 
the disappearance is prolonged, often taking years even 
on a strict diet (42). There are a few rather interesting 
studies reporting that granular IgA also exists in the 
skin of coeliac disease patients with healthy skin or 
with inflammatory skin diseases other than DH (43, 44). 
However, the number of the patients in these studies 
has been small, and further research evidence is needed 
before conclusions can be drawn about the existence of 
granular IgA in non-DH skin. For the time being, at least, 
this finding can be considered DH-specific. 
In addition to the characteristic granular deposition of 
IgA, mostly sporadic cases of fibrillary IgA deposits in 
DH have been presented (45–47). The fibrillar pattern 
of IgA appears to be more common in Japan, where it 
has been reported to occur in approximately one-third 
of patients with DH. However, Japanese patients with 
DH also show other distinct features that differ from 
Caucasian patients; the Japanese patients with DH do not 
carry the predisposing HLA-DQ2 and HLA-DQ8 hap-
lotypes, the occurrence of gluten-sensitive enteropathy 
is rare, and coeliac-disease-specific autoantibodies are 
seen only in low proportion of patients. These findings 
suggest that the pathogenesis of Japanese DH differs 
from that of Caucasian DH, and may not be dependent 
on gluten (48, 49).
Histopathological examination of lesional skin biopsy 
is not required for diagnosis of DH, but, in obscure cases, 
compatible findings with DH support the diagnosis (40). 
Ideal areas for histopathological biopsy specimen are 
an intact vesicle or erythematous skin, and the typical 
findings include non-specific subepidermal blister and 
papillary microabscesses, together with neutrophil and 
a few eosinophil infiltrates (50). However, the above-
mentioned findings alone do not allow the differentiation 
of DH from other autoimmune bullous disorders.
A recent study from Finland demonstrates that diag-
nosis of DH is not always easy. The study investigating 
the diagnostic delay of DH during the last 45 years 
detected that the duration of skin symptoms before the 
diagnosis was 2 years or more in one-third of patients 
with DH. Female sex, villous atrophy at diagnosis, and 
a DH diagnosis prior to the year 2000 were significantly 
associated with long diagnostic delay. Fortunately, the 
same study established that the diagnostic delay has 
shortened during recent decades from 12 to 8 months 
(39). Correspondingly, the diagnostic delay in coeliac 
disease has become shorter (51). 
SEROLOGICAL AND SMALL BOWEL MUCOSAL 
FINDINGS IN DERMATITIS HERPETIFORMIS
In DH, there are often circulating IgA-class autoanti-
bodies against both transglutaminase isoenzymes, TG2 
and TG3. TG2 is also the target for endomysial antibo-
dies (EmA) (52), and ELISA-based TG2- and indirect 
IF-based EmA tests can equally be utilized in clinical 
practice (Table I). However, the evaluation of EmA is 
subjective and requires skilful laboratory personnel. TG2 
antibodies have proven to be highly accurate in coeliac 
disease, but in DH these antibodies are mostly confined to 
those patients with small bowel mucosal villous atrophy, 
and hence a negative result does not exclude DH (53). 
However, together with a compatible clinical picture, TG2 
antibodies are suggestive of DH, and further, indicative of 
small bowel mucosal damage. If elevated, TG2 antibody 
measurement can further be utilized in the follow-up of 
GFD adherence after the diagnosis. Circulating TG3 
Table I. Diagnostic procedures in dermatitis herpetiformis (DH) and recommendations regarding when they should be applied
Procedure Recommendation
Patient history and physical examination
   Duration, severity and type of skin symptoms Always
   Presence of gastrointestinal and malabsorptive symptoms and signs Always
   Family history of coeliac disease and DH Always
   Presence of associated autoimmune diseases Always
Diagnostic procedures
   Direct immunofluorescence examination of perilesional skin biopsy Always
   Histopathological analysis of lesional skin biopsy In obscure cases
   Serum tissue transglutaminase or endomysial antibodies Always
   Small bowel biopsy examination Only if gastrointestinal symptoms not compatible with coeliac disease exist
   HLA DQ2 and DQ8 typing Only in obscure cases
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antibodies have been suggested to be DH-specific, but 
surprisingly, these antibodies occasionally also occur in 
the serum of coeliac disease patients without any detect-
able skin lesions (1, 54, 55). It has been shown, however, 
that in coeliac disease the affinity of the antibodies to 
TG3 is lower than in DH (1) and that TG3 reactivity 
increases with age in coeliac disease (55). Therefore, it 
can be speculated that skin symptom-free coeliac disease 
patients with TG3 reactivity are susceptible to future 
development of DH, especially if not compliant with a 
strict GFD. However, since the exact role and value of 
TG3 antibodies in DH and coeliac disease is, thus far, to 
some extent obscure, these antibodies are currently mostly 
used in research settings. 
Small bowel mucosal biopsies obtained during up-
per gastrointestinal endoscopy are not necessary for 
DH diagnosis. It is widely recognized that the majority 
of the untreated DH patients have coeliac-type small 
bowel mucosal villous atrophy, but at least one-quarter 
of the patients evince normal villous architecture (53). 
However, virtually all subjects without evident small 
bowel mucosal damage evince intestinal coeliac-type 
inflammation and/or immune response. Characteristic for 
both DH and coeliac disease is increased densities of γδ+ 
intraepithelial lymphocytes in the small bowel mucosa 
(56), but even more specific finding is the presence of 
intestinal TG2-targeted autoantibody deposits (25, 26). 
However, both of these investigations require frozen 
small bowel mucosal samples, which are not available in 
every diagnostic centre. Importantly, even though small 
bowel mucosal changes vary from inflammatory changes 
to severe villous atrophy in DH, recent evidence has 
shown that the severity of mucosal damage at diagnosis 
does not have any effects on the long-term prognosis of 
DH (57, 58), which naturally strengthens the rationale 
behind the current policy of not obtaining routine small 
bowel biopsies when DH is diagnosed. 
GLUTEN-FREE DIET AND DAPSONE TREATMENT 
IN DERMATITIS HERPETIFORMIS
The essential treatment for DH is a strict, life-long GFD. 
When adhering to a GFD, wheat, rye, barley and foods 
otherwise containing gluten are permanently excluded 
from the daily diet, but gluten-free oats (i.e. oats not 
contaminated by other cereals) are currently allowed in 
most countries and tolerated by the majority of patients 
with DH (59). Adherence to a GFD leads to healing of 
the small bowel mucosa and alleviation of the clinical 
symptoms, but total clearance of the DH rash may take 
several months or even a couple of years (17, 60). There-
fore, at the beginning of GFD treatment the individuals 
with widespread, active rash need additional treatment 
with dapsone. 
Dapsone is a sulfone drug with potent antimicrobial 
and anti-inflammatory properties, which relieves the DH 
rash and itch effectively, but has no effect on the entero-
pathy. The starting dose of dapsone should be 25–50 
mg/day. If needed, the dose can be increased gradually 
up to 100 mg/day, and then, once the rash has disap-
peared, the dose should be slowly tapered and finally 
discontinued as the GFD alone controls the rash (60). 
Dapsone is usually well tolerated when recommended 
doses are used, but side-effects are possible, of which 
dose-dependent haemolysis is the most common and, for 
example, methaemoglobinaemia, agranulocytosis and 
hepatitis less frequent. Hence, clinical and laboratory 
monitoring during treatment is necessary. In Finland 
approximately 70% of patients with DH require dapsone 
treatment after being diagnosed, and when initiated, it is 
usually needed for 2–3 years (57, 60). In rare cases of DH, 
the rash continues despite long-lasting, strict, adherence 
to a GFD. Recently this condition, named refractory 
DH, was found to occur in less than 2% of patients with 
DH (61). The patients with refractory DH in that study 
had followed a strict GFD for a mean of 16 years, but 
dapsone was still essential due to the active DH rash. 
Interestingly, despite the ongoing clinical symptoms, 
the small bowel mucosa had recovered in all subjects, 
and none had developed lymphoma, which suggests that 
refractory DH probably diverges from refractory coeliac 
disease, in which the small bowel mucosa does not heal 
on a GFD and the risk of lymphoma is increased (62). 
However, since refractory DH seems to be very rare, in 
cases of non-responsive DH, intentional or accidental 
dietary lapses are a more common reason and have to 
be excluded by dietary consultation.
Current recommendations are that treatment with a 
GFD should be life-long in DH, as in coeliac disease. 
However, there are some reports suggesting that a pro-
portion of patients with DH following a GFD could 
later re-introduce gluten to their diet without developing 
symptoms or signs of DH (60, 63, 64). Three gluten-
challenge studies have also investigated the possible 
redevelopment of gluten tolerance in DH. The first 
gluten-challenge study by Leonard et al. reported 11 out 
of 12 (92%) patients with DH relapsed with rash and 7 
(64%) of these also with villous atrophy (65). However, 
when Bardella et al. later challenged 38 GFD-treated DH 
patients with gluten, they reported 7 (18%) who did not 
manifest any type of relapse in the skin or small bowel 
during the prolonged gluten challenge (66). Very recently, 
a 12-month gluten-challenge study was performed in 19 
long-term GFD-treated DH patients in Finland (67). In 
this study, 18 (95%) of the patients relapsed in a mean of 
6 months; 15 (79%) developed DH rash, 12 of whom also 
showed small bowel villous atrophy, and 3 patients sho-
wed progression of small bowel mucosal villous atrophy 
without skin symptoms or cutaneous IgA deposits. One 
patient, however, did not show any skin symptoms or IgA 
deposits, nor did he develop intestinal villous atrophy 
or inflammation. However, a long follow-up is needed 
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before it can be concluded that gluten is truly tolerated 
by this patient, and at present, it seems that development 
of gluten tolerance in DH is rare or even non-existent, 
and life-long strict adherence to a GFD is still justified 
in all patients with DH. 
Long-term prognosis on a gluten-free diet
Coeliac disease is known for increased all-cause and 
lymphoma mortality risk (68). Therefore it is interesting 
that, in a recent Finnish DH study, the all-cause mortality 
rate in DH was, in contrast, significantly decreased (stan-
dardized mortality rate 0.70), and the lymphoma mortality 
was increased during the first 5 years after diagnosis, but 
not thereafter (58). Similarly, a previous DH study from 
the UK found a slightly, but non-significantly, reduced 
mortality rate (hazard ratio 0.93) (69). In the Finnish study, 
98% of patients with DH adhered to a GFD, which may 
explain their excellent prognosis, whereas in the study 
from the UK, data about dietary adherence was absent for 
one-third of patients (58, 69). Evidence clearly confirms 
that adherence to a GFD reduces the risk of lymphoma 
in DH, the risk of which has been shown to be similarly 
increased in DH and coeliac disease (70–72). In DH, the 
risk of gastrointestinal carcinomas has not been reported 
to be increased, which is in contrast to coeliac disease (69, 
71, 72). Also, the increased bone fracture risk associated 
with coeliac disease seems not to be a complication of 
similar extent in DH, although bone complications have 
been very rarely studied in DH (69, 73).
Quality of life (QoL) aspects in coeliac disease have 
been widely studied, but only limited evidence of DH 
and QoL exist. However, according to current know-
ledge, the QoL of patients with DH seems to be reduced, 
but importantly, already after adherence to a GFD for 1 
year, the QoL increases to the level of controls (35). The 
positive impact of GFD on DH patients’ QoL is also sup-
ported by another study, in which the Qol of long-term 
GFD-treated DH patients was equal to that of controls, 
and slightly better than that of long-term treated coeliac 
patients (74).
Similar to coeliac disease, DH has been associated 
with other autoimmune diseases, and the associations 
have mostly been explained by common genetic factors. 
In DH, the frequency of autoimmune thyroid disease 
has been reported to be as high as 4% and that of type 1 
diabetes 1–2% (75–78). In addition, Sjögren’s syndrome, 
vitiligo and alopecia areata have been reported to associ-
ate with DH, although these associations are not well do-
cumented. Most of the associated autoimmune diseases 
have been reported to develop prior to the diagnosis of 
DH, but subsequent development is also a possibility. 
A recent Finnish register study demonstrated a rather 
interesting association of DH with bullous pemphigoid 
(79). In that study, patients with previously diagnosed 
DH had a 22-fold risk for the later development of bul-
lous pemphigoid, with a mean of 3 years from diagnosis 
of DH to diagnosis of bullous pemphigoid. The authors 
speculated that a possible mechanism of this evolvement 
could be an epitope spreading phenomenon.
CONCLUSION
DH is a chronic, bullous skin disease, which is a skin 
manifestation of coeliac disease. It is suggested that 
long-lasting and undetected coeliac disease with TG2-
directed immune response serves as a prerequisite for 
the development of DH and TG3 antibody response and, 
furthermore, that more accurate and active coeliac disease 
diagnostics has resulted in a declining incidence of DH (5, 
6). The cutaneous symptoms of DH are troublesome and 
decrease the QoL of patients (35). It is therefore fortunate 
that the diagnostic delay has become shorter during recent 
decades (39). However, variable prevalence figures for 
DH in different countries, and delayed diagnosis in one-
third of patients with DH in a high prevalence area (39) 
indicate that there is still a necessity for further improve-
ment of DH diagnostics. Recognizing the cutaneous signs 
indicative of DH and IF examination of perilesional skin 
biopsy remain the cornerstones of DH diagnosis (Table 
I). Investigation of small bowel mucosal histology has no 
further value in routine diagnostics, and TG2 antibody 
testing has a supportive, but not exclusive, role in DH 
diagnosis. Future studies will presumably reveal whether 
measurement of TG3 antibody has additional value in 
DH diagnostics or in the identification of subjects at risk 
of development of DH. One future prospect is that TG3 
antibody-based diagnosis of DH could be a possibility in 
the long run, which would facilitate the diagnosis of DH 
and enable diagnostics in centres without the possibility 
of IF examination. In coeliac disease, serologically-based 
diagnosis has been recommended in children since the 
year 2012 (80), and is also utilized in adults in some 
countries, such as Finland. 
According to current knowledge, strict life-long ad-
herence to GFD is justified in all patients with DH. The 
prognosis seems to be excellent in those individuals 
with DH who follow the diet rigorously, but other than 
adherence to a GFD, little is known about the factors 
that influence the development of complications or as-
sociated diseases of DH and mortality. Instead, it has 
been shown that the degree of villous atrophy has no 
effect on the above-mentioned outcomes of DH (57, 58). 
Factual non-responsiveness to GFD is rare in DH, but, 
in general, refractory DH seems to have better prognosis 
compared with refractory coeliac disease (61). However, 
current knowledge of refractory DH is scarce and more 
research evidence is needed in order to elaborate this en-
tity more thoroughly. In addition, the differing mortality 
trends currently existing among DH and coeliac disease 
patients adhering to the same diet is an interesting topic 
for future studies. 
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